Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Silo Pharma (SILO) EBITDA (2016 - 2025)

Historic EBITDA for Silo Pharma (SILO) over the last 13 years, with Q3 2025 value amounting to -$1.1 million.

  • Silo Pharma's EBITDA fell 2089.48% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.1 million, marking a year-over-year decrease of 3514.09%. This contributed to the annual value of -$4.4 million for FY2024, which is 1827.19% down from last year.
  • Silo Pharma's EBITDA amounted to -$1.1 million in Q3 2025, which was down 2089.48% from -$1.2 million recorded in Q2 2025.
  • In the past 5 years, Silo Pharma's EBITDA ranged from a high of -$436849.0 in Q2 2021 and a low of -$1.7 million during Q4 2024
  • Its 5-year average for EBITDA is -$951646.3, with a median of -$942416.0 in 2021.
  • Over the last 5 years, Silo Pharma's EBITDA had its largest YoY gain of 5617.02% in 2021, and its largest YoY loss of 46547.9% in 2021.
  • Over the past 5 years, Silo Pharma's EBITDA (Quarter) stood at -$942416.0 in 2021, then plummeted by 76.44% to -$1.7 million in 2022, then surged by 32.24% to -$1.1 million in 2023, then plummeted by 55.15% to -$1.7 million in 2024, then soared by 36.58% to -$1.1 million in 2025.
  • Its EBITDA was -$1.1 million in Q3 2025, compared to -$1.2 million in Q2 2025 and -$1.0 million in Q1 2025.